亞盛醫藥-B(06855.HK):在2020年美國血液學學會年會公佈HQP1351(奧瑞巴替尼)關鍵性註冊II期研究的積極數據
格隆匯 12 月 8日丨亞盛醫藥-B(06855.HK)發佈公告,公司在研原創1類新藥HQP1351(擬定中文通用名:奧瑞巴替尼)的兩項關鍵性註冊II期臨牀的積極研究結果已在第62屆美國血液學會(ASH)年會上以口頭報告的形式公佈,數據令人鼓舞。該兩項臨牀研究的主要研究者、北京大學人民醫院血液科副主任江倩教授為報告人。這是繼2018、2019年之後,HQP1351的臨牀進展連續第三次入選ASH年會口頭報告,充分顯示了國際血液學界對該藥物安全性和療效的認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.